Alnylam Pharmaceuticals (ALNY) Enterprise Value (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Enterprise Value data on file, last reported at -$3.3 billion in Q2 2026.

• Quarterly Enterprise Value fell 15.77% year-over-year to -$3.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$3.3 billion (down 15.77% YoY) and the FY2025 annual result came in at -$2.9 billion, down 8.18% from the prior year.
• Enterprise Value fell to -$3.3 billion in Q2 2026, from -$3.0 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$2.0 billion in Q2 2023 to a low of -$3.3 billion in Q2 2026.
• A 5-year average of -$2.5 billion and a median of -$2.5 billion in 2023 frame the typical range for Enterprise Value.
• The widest YoY moves for Enterprise Value: up 8.62% in 2022, down 33.58% in 2022.
• Tracing ALNY's Enterprise Value over 5 years: stood at -$2.2 billion in 2022, then decreased by 12.08% to -$2.4 billion in 2023, then dropped by 10.72% to -$2.7 billion in 2024, then dropped by 8.18% to -$2.9 billion in 2025, then retreated by 13.74% to -$3.3 billion in 2026.
• The last three Enterprise Value figures came in at -$3.3 billion (Q2 2026), -$3.0 billion (Q1 2026), and -$2.9 billion (Q4 2025), per Business Quant data.